Table 1.

Summary of studies concerning radiofrequency ablation

Authors	Number of patients	Lesion type	Location	Treatment type	Approach	Needle	Mean treatment duration	Conclusion
D’Onofrio et al[8]	18	Pancreatic ductal adenocarcinoma	Head	Radiofrequency ablation	Percutaneous with US	17 G	3 min and 13 s	High success rate, with 40% of cases showing CA 19.9 reduction
Carrafiello et al[26]	1	Pancreatic metastases from renal cell	Body-tail	Radiofrequency ablation	Percutaneous with CT	19 G	8 min and 35 s	RFA is feasible for
Carrafiello et al[26]	1	Pancreatic metastases from renal cell	Body-tail	Radiofrequency ablation	Percutaneous with CT	19 G	8 min and 35 s	metastatic lesions at body-tail
Limmer et al[27]	1	Insulinoma	Body-tail	Radiofrequency ablation	Percutaneous with CT	16 G	18 min	RFA proved to be a clinically successful
Limmer et al[27]	1	Insulinoma	Body-tail	Radiofrequency ablation	Percutaneous with CT	16 G	18 min	procedure
Wu et al[28]	1	Gastrinoma	Tail	Radiofrequency ablation	Percutaneous transplenic with CT	-	-	Percutaneous transplenic RFA is feasible
Singh et al[29]	11	Pancreatic ductal adenocarcinoma	-	Radiofrequency ablation	1 percutaneous with CT + 10 laparoscopic	-	-	RFA is a safe and feasible technique of tumor cytoreduction
Rossi et al[30]	8	Pancreatic neuroendocrine tumors	Head and body-tail	Radiofrequency ablation	Percutaneous with CT	17 and 19 G	9 min	RFA is a feasible, safe, and effective option

US: Ultrasound; CT: Computed tomography; RFA: Radiofrequency ablation.